OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.
Completed
- Conditions
- Diabetes
- Registration Number
- NCT00681850
- Lead Sponsor
- AstraZeneca
- Brief Summary
Demonstrate that the use of benchmarking improves quality of patient care, in particular the control of diabetes, lipids and blood pressure, by determining the percentage of patients in the benchmarking group achieving pre-set targets for HbA1c 14,18, LDL-cholesterol16,18 and Systolic Blood Pressure17,18 versus control group (non-benchmarking group) after 12 months of follow-up.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 4027
Inclusion Criteria
- Provision of informed Consent
- Patients suffering from diabetes type II, insulin dependent or not insulin dependent.
Read More
Exclusion Criteria
- Type I diabetes
- Pregnancy diabetes
- Hospitalisation, as this is a primary care study
- Patients who are member of the Belgian Diabetes Convention
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1c, LDL-cholesterol, Systolic Blood Pressure Visit 1; Visit 2 (after approximately 4 months after visit 1); Visit 3 (after approximately 8 months after visit 1); Visit 4 (after approximately 12 months after visit 1)
- Secondary Outcome Measures
Name Time Method Glycaemia, Triglycerides, Total and HDL-Cholesterol, Diastolic Blood Pressure, Waist circumference, Smoking habits, Microalbuminuria, Body Mass Index, Physical activity (Rating scale and step counter), Degree of ophthalmic control and dietary advice Visit 1Visit 2 (after approximately 4 months after visit 1)Visit 3 (after approximately 8 months after visit 1)Visit 4 (after approximately 12 months after visit 1)
Trial Locations
- Locations (1)
Research Site
🇬🇧Westbury, United Kingdom